Enhancing DNA Vaccine Potency by Combining a Strategy to Prolong Dendritic Cell Life with Intracellular Targeting Strategies 1
暂无分享,去创建一个
Tae Woo Kim | T. Wu | C. Hung | D. Boyd | J. Juang | Liangmei He | Jeong Won Kim | J. Hardwick | David A. K. Boyd | J. Kim
[1] Tae Woo Kim,et al. Enhancing DNA vaccine potency by coadministration of DNA encoding antiapoptotic proteins. , 2003, The Journal of clinical investigation.
[2] G. Linette,et al. Antimelanoma Activity of CTL Generated from Peripheral Blood Mononuclear Cells After Stimulation with Autologous Dendritic Cells Pulsed with Melanoma gp100 Peptide G209-2M Is Correlated to TCR Avidity , 2002, The Journal of Immunology.
[3] F. Sallusto,et al. T cell priming by dendritic cells: thresholds for proliferation, differentiation and death and intraclonal functional diversification , 2002, European journal of immunology.
[4] T. Schumacher,et al. Expression of the Serpin Serine Protease Inhibitor 6 Protects Dendritic Cells from Cytotoxic T Lymphocyte–Induced Apoptosis , 2001, The Journal of experimental medicine.
[5] T. Wu,et al. Tumor-specific immunity and antiangiogenesis generated by a DNA vaccine encoding calreticulin linked to a tumor antigen. , 2001, The Journal of clinical investigation.
[6] L. Bianchi,et al. HPV-related neoplasias in HIV-infected individuals , 2001 .
[7] T. Wu,et al. Enhancement of Sindbis Virus Self-Replicating RNA Vaccine Potency by Linkage of Herpes Simplex Virus Type 1 VP22 Protein to Antigen , 2001, Journal of Virology.
[8] Jay A. Berzofsky,et al. High-Avidity CTL Exploit Two Complementary Mechanisms to Provide Better Protection Against Viral Infection Than Low-Avidity CTL , 2001, The Journal of Immunology.
[9] I Lebedeva,et al. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity. , 2000, Cancer research.
[10] T. Wu,et al. Enhancement of DNA vaccine potency by linkage of antigen gene to an HSP70 gene. , 2000, Cancer research.
[11] R. Kurman,et al. Targeting human papillomavirus type 16 E7 to the endosomal/lysosomal compartment enhances the antitumor immunity of DNA vaccines against murine human papillomavirus type 16 E7-expressing tumors. , 1999, Human gene therapy.
[12] M. Levitt,et al. The generation of human dendritic and NK cells from hemopoietic progenitors induced by interleukin‐15 , 1999, Journal of leukocyte biology.
[13] Simon C Watkins,et al. CD154 inhibits tumor‐induced apoptosis in dendritic cells and tumor growth , 1999, European journal of immunology.
[14] E. Okada,et al. IL-15 expression plasmid enhances cell-mediated immunity induced by an HIV-1 DNA vaccine. , 1999, Vaccine.
[15] T. Wright,et al. Human immunodeficiency virus infection and female lower genital tract malignancy. , 1999, Current opinion in obstetrics & gynecology.
[16] R. Steinman,et al. TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.
[17] T. Kipps,et al. Immunostimulatory effects of a plasmid expressing CD40 ligand (CD154) on gene immunization. , 1997, Journal of immunology.
[18] F. Sallusto,et al. Origin, maturation and antigen presenting function of dendritic cells. , 1997, Current opinion in immunology.
[19] J. Kim,et al. In vivo engineering of a cellular immune response by coadministration of IL-12 expression vector with a DNA immunogen. , 1997, Journal of immunology.
[20] Simon C Watkins,et al. DNA–based immunization by in vivo transfection of dendritic cells , 1996, Nature Medicine.
[21] J. Berzofsky,et al. Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[22] E. Cheng,et al. Bax-independent inhibition of apoptosis by Bcl-XL , 1996, Nature.
[23] Kathleen R. Cho,et al. Engineering an intracellular pathway for major histocompatibility complex class II presentation of antigens. , 1995, Proceedings of the National Academy of Sciences of the United States of America.
[24] A. Boudewijn,et al. Interleukin-12 synergizes with interleukin-3 and steel factor to enhance recovery of murine hemopoietic stem cells in liquid culture. , 1993, Leukemia.
[25] T. Wu,et al. HPV DNA vaccines. , 2003, Frontiers in bioscience : a journal and virtual library.
[26] T. Wu,et al. Repeated DNA vaccinations elicited qualitatively different cytotoxic T lymphocytes and improved protective antitumor effects. , 2002, Journal of biomedical science.
[27] A. Del Mistro,et al. HPV-related neoplasias in HIV-infected individuals. , 2001, European journal of cancer.
[28] S. Gurunathan,et al. DNA vaccines: immunology, application, and optimization*. , 2000, Annual review of immunology.
[29] F. Guarnieri,et al. Treatment of established tumors with a novel vaccine that enhances major histocompatibility class II presentation of tumor antigen. , 1996, Cancer research.